Daily Respiratory Research Analysis
Three studies stand out today: a NEJM analysis of 46 U.S. human H5N1 cases showing predominantly mild, conjunctivitis-predominant illness with no detected human-to-human transmission but suboptimal PPE use; a retrospective national study linking higher GP chest X-ray use to earlier-stage lung cancer diagnosis and modest survival gains; and a preclinical Molecular Therapy report demonstrating a mucosal ‘inverted HA’ extracellular vesicle vaccine that elicits broad, stalk-focused influenza immunit
Summary
Three studies stand out today: a NEJM analysis of 46 U.S. human H5N1 cases showing predominantly mild, conjunctivitis-predominant illness with no detected human-to-human transmission but suboptimal PPE use; a retrospective national study linking higher GP chest X-ray use to earlier-stage lung cancer diagnosis and modest survival gains; and a preclinical Molecular Therapy report demonstrating a mucosal ‘inverted HA’ extracellular vesicle vaccine that elicits broad, stalk-focused influenza immunity and cross-protection in mice.
Research Themes
- Zoonotic respiratory threats and public health response (H5N1 in humans)
- Primary care imaging and earlier lung cancer diagnosis
- Innovative mucosal vaccine platforms for broad influenza protection
Selected Articles
1. Highly Pathogenic Avian Influenza A(H5N1) Virus Infections in Humans.
Among 46 U.S. human H5N1 infections, illness was predominantly mild and ocular (93% conjunctivitis), with no hospitalizations or deaths and no detected transmission to 97 household contacts. Despite prompt antiviral use, PPE use was suboptimal, underscoring the need for strengthened occupational protections (especially eye protection) in exposed workers.
Impact: Timely human data on H5N1 in an expanding U.S. epizootic informs risk assessment, clinical vigilance, and occupational safety policies.
Clinical Implications: Clinicians should screen exposed workers for ocular symptoms, consider early antivirals, and reinforce PPE including eye protection. Public health should address PPE access, training, and surveillance to detect non-respiratory presentations.
Key Findings
- Among 46 cases, 20 had poultry exposure, 25 had dairy cow exposure, and 1 had no identified exposure.
- Illness was predominantly mild: 93% conjunctivitis, 49% fever, 36% respiratory symptoms; no hospitalizations or deaths.
- No secondary cases were detected among 97 household contacts.
- Most patients (87%) received oseltamivir within a median of 2 days of symptom onset.
- PPE use among exposed workers was suboptimal: gloves 71%, eye protection 60%, masks 47%.
Methodological Strengths
- Standardized case-reporting linked with CDC H5 subtyping laboratory confirmation
- National scope with systematic ascertainment and contact assessment
Limitations
- Descriptive surveillance with relatively small sample size limits precision
- Potential ascertainment bias and limited follow-up for delayed complications
Future Directions: Evaluate determinants of ocular-predominant disease, optimize PPE strategies (especially eye protection) in agricultural settings, and continue genomic/epidemiologic surveillance for changes in transmissibility or severity.
BACKGROUND: Highly pathogenic avian influenza A(H5N1) viruses have caused widespread infections in dairy cows and poultry in the United States, with sporadic human cases. We describe characteristics of human A(H5N1) cases identified from March through October 2024 in the United States. METHODS: We analyzed data from persons with laboratory-confirmed A(H5N1) virus infection using a standardized case-report form linked to laboratory results from the Centers for Disease Control and Prevention influenza A/H5 subtyping kit. RESULTS: Of 46 case patients, 20 were exposed to infected poultry, 25 were exposed to infected or presumably infected dairy cows, and 1 had no identified exposure; that patient was hospitalized with nonrespiratory symptoms, and A(H5N1) virus infection was detected through routine surveillance. Among the 45 case patients with animal exposures, the median age was 34 years, and all had mild A(H5N1) illness; none were hospitalized, and none died. A total of 42 patients (93%) had conjunctivitis, 22 (49%) had fever, and 16 (36%) had respiratory symptoms; 15 (33%) had conjunctivitis only. The median duration of illness among 16 patients with available data was 4 days (range, 1 to 8). Most patients (87%) received oseltamivir; oseltamivir was started a median of 2 days after symptom onset. No additional cases were identified among the 97 household contacts of case patients with animal exposures. The types of personal protective equipment (PPE) that were most commonly used by workers exposed to infected animals were gloves (71%), eye protection (60%), and face masks (47%). CONCLUSIONS: In the cases identified to date, A(H5N1) viruses generally caused mild illness, mostly conjunctivitis, of short duration, predominantly in U.S. adults exposed to infected animals; most patients received prompt antiviral treatment. No evidence of human-to-human A(H5N1) transmission was identified. PPE use among occupationally exposed persons was suboptimal, which suggests that additional strategies are needed to reduce exposure risk. (Funded by the Centers for Disease Control and Prevention.).
2. Inverted HA-EV immunization elicits stalk-specific influenza immunity and cross-protection in mice.
An extracellular vesicle (EV) platform displaying ‘inverted’ influenza HA (stalk exposed) via intranasal delivery induced robust stalk-specific and mucosal immunity and protected mice against heterologous strains. A549-derived EVs and multivalent HA conjugation broadened cross-reactive antibody and cellular responses.
Impact: Proposes a biocompatible mucosal vaccine platform achieving stalk-focused breadth—an important step toward a universal influenza vaccine and respiratory mucosal immunity.
Clinical Implications: While preclinical, the approach suggests a feasible intranasal strategy to induce local IgA and stalk-focused breadth, informing next-generation, cross-protective influenza vaccine design.
Key Findings
- EVs displaying inverted HA exposed the conserved stalk and reduced head immunodominance, enhancing breadth.
- Intranasal immunization induced strong serum and mucosal responses and protected mice against heterologous strains.
- A549-derived EVs generated superior cross-reactive antibodies and protection compared with other EV sources.
- Multivalent HA conjugation on EVs elicited broadly cross-reactive antibody and cellular responses.
Methodological Strengths
- Rational antigen display (stalk exposure) with a biocompatible EV delivery platform
- Multiple comparative in vivo experiments (EV sources, multivalency) with functional protection readouts
Limitations
- Preclinical murine model; human safety, dosing, and durability unknown
- Manufacturing and standardization of EV vaccines require further development
Future Directions: Advance to GLP toxicology, define correlates of mucosal protection (e.g., stalk-specific IgA), and assess breadth against drifted/shifted strains in higher-order models.
Enhancing protective immunity in the respiratory tract is crucial to combat influenza infection and transmission. Developing mucosal universal influenza vaccines requires effective delivery platforms to overcome the respiratory mucosal barrier and stimulate appropriate innate immune reactions, thereby bridging adaptive immune responses with minimal necessary inflammation. Meanwhile, the vaccine platforms must be biocompatible. This study employed cell-derived extracellular vesicles (EVs) as a mucosal universal influenza vaccine platform. By conjugating influenza hemagglutinin (HA) onto EV surfaces through HA-receptor interaction, we achieved an upside-down (inverted) influenza HA configuration that exposed the conserved HA stalk region while partially hiding the globular head domain. Intranasal immunization with the resulting EVs induced robust HA stalk- and virus-specific serum antibody and mucosal immune responses in mice, protecting against heterologous virus infection. Notably, EVs derived from the lung epithelial cell line A549 induced superior cross-reactive antibodies and enhanced protection upon intranasal immunization. EVs conjugating multivalent HA elicited broadly cross-reactive antibody and cellular responses against different influenza strains. Our results demonstrated that EVs conjugating multiple inverted HAs represented an effective strategy for developing a mucosal universal influenza vaccine.
3. General practice chest X-ray rate is associated with earlier lung cancer diagnosis and reduced all-cause mortality: a retrospective observational study.
Across 7,409 English practices and 192,631 lung cancer patients, higher practice-level use of chest X-ray was associated with fewer late-stage (III/IV) diagnoses and modestly improved survival, after adjustment for key population factors. Findings support using CXR to expedite assessment of symptomatic patients in primary care.
Impact: Large, real-world evidence linking primary care diagnostic behavior to stage shift and survival in lung cancer can inform policy and quality metrics.
Clinical Implications: Encourage timely CXR in symptomatic adults with potential lung cancer features, with system support (access and reporting) to reduce late-stage presentations.
Key Findings
- Higher practice CXR rates were associated with fewer stage III/IV diagnoses (adjusted OR 0.87, 95% CI 0.83–0.92).
- Slight improvements in 1-year and 5-year survival were observed in practices with higher CXR use.
- Associations persisted after adjustment for age, smoking prevalence, COPD/heart failure prevalence, ethnicity, and deprivation.
Methodological Strengths
- Large national dataset linking cancer registry with practice-level imaging utilization
- Adjusted analyses for multiple population-level confounders and stratified comparisons
Limitations
- Observational, practice-level (ecological) exposure may not reflect individual-level decisions
- Residual confounding and unmeasured factors (e.g., referral pathways, radiology turnaround) may influence outcomes
Future Directions: Prospective interventions to optimize CXR access/triage in primary care and evaluate downstream effects on diagnostic intervals, staging, and lung cancer-specific mortality.
BACKGROUND: Evidence is equivocal on whether general practice rates of investigation in symptomatic patients using chest X-ray (CXR) affect outcomes. AIM: To determine whether there is an association between rates of CXR requested in general practice and lung cancer outcomes. DESIGN AND SETTING: Observational study using data on English general practices. METHOD: Cancer registry data for patients diagnosed with lung cancer in 2014-2018 were linked to data on general practice CXRs from 2013 until 2017. Cancer stage at diagnosis (I/II versus III/IV) and 1-year and 5-year survival rates (conditional on survival to 1 year) post-diagnosis were reported by general practice quintile of CXR rate, with adjustment for population differences (age, smoking, prevalence of chronic obstructive pulmonary disease and heart failure, ethnicity, and deprivation) and by unadjusted category (low, medium, and high). RESULTS: In total, 192 631 patient records and CXR rates for 7409 practices were obtained. Practices in the highest quintile of CXR rate had fewer cancers diagnosed at stage III/IV compared with those in the lowest quintile (odds ratio [OR] 0.87, 95% confidence interval [CI] = 0.83 to 0.92, CONCLUSION: Patients registered at general practices with higher CXR use have a favourable stage distribution and slightly better survival. This supports the use of CXR in promoting earlier diagnosis of symptomatic lung cancer in general practice.